Protein biomarkers of ovarian cancer: The forest and the trees

Future Oncology

Volumn 8, Issue 1, 2012, Pages 55-71

  Nolen, Brian M ^a,b   Lokshin, Anna E ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; host response; ovarian cancer; pelvic mass; screening; tumor microenvironment

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CHEMOKINE; CLAUDIN; CXCL13 CHEMOKINE; CYSTATIN; CYSTATIN C; CYTOKINE; ENTACTIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 28; INTERLEUKIN 33; MATRIPTASE; OSTEOPONTIN; PROSTASIN; TETRANECTIN; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; CELL HETEROGENEITY; CLEAR CELL CARCINOMA; DOPPLER FLOWMETRY; EARLY DIAGNOSIS; ENDOMETRIOID CARCINOMA; FOREST; HUMAN; IMAGING; IMMUNOASSAY; MORTALITY; MUCINOUS CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TREE;

ANIMALS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 83655191714     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.135     Document Type: Review

References (144)

1. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl 2 and matrix metalloproteinase 2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int. J. Oncol. 19(3), 537-542 (2001).
2. Brustmann H, Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol. Oncol. 84(1), 47-52 (2002). (Pubitemid 34056465)
3. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 19(1), 3-10 (2000). (Pubitemid 30439309)
4. Baker TR, Piver MS. Etiology, biology, and epidemiology of ovarian cancer. Semin. Surg. Oncol. 10(4), 242-248 (1994).
5. Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J. Clin. Epidemiol. 44(4-5), 365-380 (1991).
6. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell. Proteomics 3(4), 355-366 (2004). (Pubitemid 38702089)
7. Menon U, Jacobs IJ. Ovarian cancer screening in the general population: current status. Int. J. Gynecol. Cancer 11(Suppl. 1), 3-6 (2001). (Pubitemid 32751377)
8. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int. J. Biol. Markers 13(4), 179-187 (1998). (Pubitemid 29178546)
9. Kinkel K, Hricak H, Lu Y, Tsuda K, Filly RA. US characterization of ovarian masses: a meta-analysis. Radiology 217(3), 803-811 (2000).
10. Fishman DA, Cohen L, Blank SV et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am. J. Obstet. Gynecol. 192(4), 1214-1221; discussion 1221-1212 (2005).
11. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer 42(5), 677-680 (1988). (Pubitemid 19008906)
12. Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309(15), 883-887 (1983). (Pubitemid 13014028)
13. Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet. Gynecol. 74(3 Pt 1), 384-387 (1989). (Pubitemid 19213928)
14. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4(1), 1-12 (1989). (Pubitemid 19069900)
15. Woolas RP, Xu FJ, Jacobs IJ et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl Cancer Inst. 85(21), 1748-1751 (1993). (Pubitemid 23320845)
16. Slotman BJ, Rao BR. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res. 8(3), 417-434 (1988).
17. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(Suppl. 2), 517-523 (1993). (Pubitemid 23021245)
18. Gocze P, Vahrson H: Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies). Orv. Hetil. 134(17), 915-918 (1993).
19. Molina R, Filella X, Jo J, Agusti C, Ballesta AM. CA 125 in biological fluids. Int. J. Biol. Markers 13(4), 224-230 (1998). (Pubitemid 29178554)
20. Kaku T, Ogawa S, Kawano Y et al. Histological classification of ovarian cancer. Med. Electron Microsc. 36(1), 9-17 (2003). (Pubitemid 36504385)
21. Neesham D. Ovarian cancer screening. Aust. Fam. Physician 36(3), 126-128 (2007).
22. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N. Engl. J. Med. 361(2), 170-177 (2009).
23. Johnson CC, Kessel B, Riley TL et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol. Oncol. 110(3), 383-389 (2008).
24. Menon U. Ovarian cancer screening. CMAJ 171(4), 323-324 (2004). (Pubitemid 39127980)
25. Urban N, McIntosh MW, Andersen M, Karlan BY. Ovarian cancer screening. Hematol. Oncol. Clin. North Am. 17(4), 989-1005, ix (2003). (Pubitemid 37022154)
26. Calogne N. Screening for ovarian cancer: recommendation statement. Ann. Fam. Med. 2(3), 260-262 (2004).
27. US Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. Am. Fam. Physician 71(4), 759-762 (2005).
28. ACOG committee opinion. Role of loop electrosurgical excision procedure in the evaluation of abnormal Pap test results. Number 195, November 1997. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int. J. Gynaecol. Obstet. 61(2), 203-204 (1998).
29. Brown DL, Andreotti RF, Lee SI et al. ACR appropriateness criteria(c) ovarian cancer screening. Ultrasound Q. 26(4), 219-223 (2010).
30. Partridge E, Kreimer AR, Greenlee RT et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113(4), 775-782 (2009).
31. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22), 2295-2303 (2011).
32. Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10(4), 327-340 (2009).
33. Ueland FR, Depriest PD, Pavlik EJ, Kryscio RJ, Van Nagell JR Jr. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol. Oncol. 91(1), 46-50 (2003). (Pubitemid 37188592)
34. Buys SS, Partridge E, Greene MH et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 193(5), 1630-1639 (2005). (Pubitemid 41540458)
35. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93(14), 1054-1061 (2001). (Pubitemid 32717537)
36. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 212(4490), 53-55 (1981). (Pubitemid 11114676)
37. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 121, 439-462 (1965).
38. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68(5), 1331-1337 (1981). (Pubitemid 12235035)
39. Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. Gynecol. Oncol. 120(1), 152-157 (2011).
40. Zhang B, Barekati Z, Kohler C et al. Proteomics and biomarkers for ovarian cancer diagnosis. Ann. Clin. Lab. Sci. 40(3), 218-225 (2010).
41. Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J. Proteomics 73(12), 2291-2305 (2010).
42. Dutta S, Wang FQ, Phalen A, Fishman DA. Biomarkers for ovarian cancer detection and therapy. Cancer Biol. Ther. 9(9), 668-677 (2010).
43. Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond. Engl.) 4, 27-40 (2008).
44. Coticchia CM, Yang J, Moses MA. Ovarian cancer biomarkers: current options and future promise. J. Natl Compr. Canc. Netw. 6(8), 795-802 (2008).
45. Mclemore MR, Miaskowski C, Aouizerat BE, Chen LM, Dodd M. Rules of tumor cell development and their application to biomarkers for ovarian cancer. Oncol. Nurs. Forum 35(3), 403-409 (2008).
46. Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer. Dis. Markers 23(5-6), 419-431 (2007). (Pubitemid 350171264)
47. Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis. Markers 23(5-6), 397-410 (2007). (Pubitemid 350171267)
48. Munkarah A, Chatterjee M, Tainsky MA. Update on ovarian cancer screening. Curr. Opin. Obstet. Gynecol. 19(1), 22-26 (2007). (Pubitemid 46095868)
49. Bast RC Jr, Badgwell D, Lu Z et al. New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 15(Suppl. 3), 274-281 (2005). (Pubitemid 43096594)
50. Nossov V, Amneus M, Su F et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA 125? Am. J. Obstet. Gynecol. 199(3), 215-223 (2008).
51. Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 28(13), 2159-2166 (2010).
52. Bertenshaw GP, Yip P, Seshaiah P et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 17(10), 2872-2881 (2008).
53. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB et al. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5(14), 3790-3797 (2005). (Pubitemid 41393309)
54. Lin B, White JT, Wu J et al. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin. Appl. 3(7), 853-861 (2009).
55. Qian WJ, Kaleta DT, Petritis BO et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12- SuperMix immunoaffinity separation strategy. Mol. Cell. Proteomics 7(10), 1963-1973 (2008).
56. Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA 102(21), 7677-7682 (2005). (Pubitemid 40741030)
57. Amonkar SD, Bertenshaw GP, Chen TH et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS ONE 4(2), E4599 (2009).
58. Edgell T, Martin-Roussety G, Barker G et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J. Cancer Res. Clin. Oncol. 136(7), 1079-1088 (2010).
59. Skates SJ, Horick N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA 125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22(20), 4059-4066 (2004). (Pubitemid 41185174)
60. Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14(4), 1065-1072 (2008). (Pubitemid 351302552)
61. Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64(16), 5882-5890 (2004). (Pubitemid 39095590)
62. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27(2), 151-160 (2008). (Pubitemid 351450677)
63. Shin H, Sheu B, Joseph M, Markey MK. Guilt-by-association feature selection: identifying biomarkers from proteomic profiles. J. Biomed. Inform. 41(1), 124-136 (2008).
64. Cramer DW, Bast RC Jr, Berg CD et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev. Res. (Phila.) 4(3), 365-374 (2011).
65. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J. Natl Cancer Inst. 102(19), 1462-1467 (2010).
66. Levanon K, Ng V, Piao HY et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29(8), 1103-1113 (2010).
67. Faca VM, Ventura AP, Fitzgibbon MP et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE 3(6), E2425 (2008).
68. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5(17), 4589-4596 (2005). (Pubitemid 41739936)
69. Gaytan F, Morales C, Barreiro ML et al. Expression of growth hormone secretagogue receptor type 1a, the functional ghrelin receptor, in human ovarian surface epithelium, mullerian duct derivatives, and ovarian tumors. J. Clin. Endocrinol. Metab. 90(3), 1798-1804 (2005). (Pubitemid 40464054)
70. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149(1), 273-282 (1996). (Pubitemid 26230998)
71. Shima I, Sasaguri Y, Kusukawa J et al. Production of matrix metalloproteinase 9 (92 kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Br. J. Cancer 67(4), 721-727 (1993). (Pubitemid 23101549)
72. Levina VV, Nolen B, Su Y et al. Biological significance of prolactin in gynecologic cancers. Cancer Res. 69(12), 5226-5233 (2009).
73. Turner GA, Goodarzi MT, Thompson S. Glycosylation of alpha 1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Glycoconj. J. 12(3), 211-218 (1995).
74. Partridge EA, Le Roy C, Di Guglielmo GM et al. Regulation of cytokine receptors by Golgi N glycan processing and endocytosis. Science 306(5693), 120-124 (2004). (Pubitemid 39451953)
75. Saldova R, Royle L, Radcliffe CM et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17(12), 1344-1356 (2007). (Pubitemid 350131311)
76. Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ, Van Dijk E, Meloen RH. Monitoring health by values of acute phase proteins. Acta Histochem. 108(3), 229-232 (2006). (Pubitemid 44026505)
77. Ceciliani F, Giordano A, Spagnolo V. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept. Lett. 9(3), 211-223 (2002).
78. Pritzker KP. Cancer biomarkers: easier said than done. Clin. Chem. 48(8), 1147-1150 (2002). (Pubitemid 34809818)
79. Diamandis EP, Van Der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin. Cancer Res. 11(3), 963-965 (2005). (Pubitemid 40175741)
80. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360(9327), 170; author reply 170-171 (2002).
81. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96(5), 353-356 (2004). (Pubitemid 38351297)
82. Slattery ML, Fitzpatrick FA. Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology. Cancer Prev. Res. (Phila.) 2(11), 922-930 (2009).
83. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J. 313(Pt 1), 17-29 (1996). (Pubitemid 26013419)
84. Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch. Surg. 391(5), 499-510 (2006). (Pubitemid 44337612)
85. O'byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer 85(4), 473-483 (2001). (Pubitemid 32808267)
86. Naldini A, Pucci A, Bernini C, Carraro F. Regulation of angiogenesis by Th1 and Th2 type cytokines. Curr. Pharm. Des. 9(7), 511-519 (2003). (Pubitemid 36221719)
87. Aldinucci D, Poletto D, Nanni P et al. CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. Exp. Hematol. 30(11), 1283-1292 (2002). (Pubitemid 35287581)
88. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 99(8), 1501-1506 (2008).
89. Culig Z. Cytokine disbalance in common human cancers. Biochim. Biophys. Acta 1813(2), 308-314 (2011).
90. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat. Res. 659(1-2), 15-30 (2008).
91. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit. Rev. Oncol. Hematol. 66(3), 208-217 (2008).
92. Sharma RA, Dalgleish AG, Steward WP, O'Byrne KJ. Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncol. Rep. 10(5), 1625-1631 (2003).
93. Kikuchi T, Abe T, Yaekashiwa M et al. Secretory leukoprotease inhibitor augments hepatocyte growth factor production in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 23(3), 364-370 (2000).
94. Dabbagh K, Laurent GJ, Shock A, Leoni P, Papakrivopoulou J, Chambers RC. Alpha 1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways. J. Cell. Physiol. 186(1), 73-81 (2001).
95. Nasulewicz A, Mazur A, Opolski A. Role of copper in tumour angiogenesis - clinical implications. J. Trace Elem. Med. Biol. 18(1), 1-8 (2004). (Pubitemid 39285958)
96. Zhu CS, Pinsky PF, Cramer DW et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev. Res. (Phila.) 4(3), 375-383 (2011).
97. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta 1785(2), 232-265 (2008).
98. Su F, Kozak KR, Imaizumi S et al. Apolipoprotein A I (apoA I) and apoA I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc. Natl Acad. Sci. USA 107(46), 19997-20002 (2010).
99. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Stat. Soc. B (Methodol.) 57(1), 289-300 (1995).
100. Castracane VD, Gimpel T, Goldzieher JW. Diagnosis of menopause: ratios of FSH/LH? Fertil. Steril. 66(5), 866 (1996). (Pubitemid 26357605)
101. Czygan PJ. Plasma levels of FSH and LH during the menstrual cycle, the menopause and in the course of gestagen treatment. Acta Endocrinol. Suppl. (Copenh.) 152, 2 (1971).
102. Andersen TT, Curatolo LM, Reichert LE Jr. Follitropin binding to receptors in testis: studies on the reversibility and thermodynamics of the reaction. Mol. Cell. Endocrinol. 33(1), 37-52 (1983). (Pubitemid 14245229)
103. Moore LE, Fung ET, Mcguire M et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol. Biomarkers Prev. 15(9), 1641-1646 (2006). (Pubitemid 44497099)
104. Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am. J. Obstet. Gynecol. 200(6), 639 e631-e635 (2009).
105. Levina V, Nolen BM, Marrangoni AM et al. Role of eotaxin 1 signaling in ovarian cancer. Clin. Cancer Res. 15(8), 2647-2656 (2009).
106. Abbott KL, Lim JM, Wells L, Benigno BB, Mcdonald JF, Pierce M. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics 10(3), 470-481 (2010).
107. Mirshahi M, Soria J, Soria C, Bertrand O, Basdevant A. Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). Thromb. Res. 48(3), 279-289 (1987). (Pubitemid 18026049)
108. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum. Pathol. 42(7), 918-931 (2011).
109. De Bruijn HW, Ten Hoor KA, Boonstra H, Marrink J, Krans M, Aalders JG. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. Tumour Biol. 14(2), 105-115 (1993). (Pubitemid 23255790)
110. Brun JL, Cortez A, Commo F, Uzan S, Rouzier R, Darai E. Serous and mucinous ovarian tumors express different profiles of MMP 2, 7, 9, MT1 MMP, and TIMP 1 and 2. Int. J. Oncol. 33(6), 1239-1246 (2008).
111. Murthi P, Barker G, Nowell CJ et al. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol. Oncol. 92(1), 80-88 (2004). (Pubitemid 38147375)
112. Adley BP, Gleason KJ, Yang XJ, Stack MS. Expression of membrane type 1 matrix metalloproteinase (MMP 14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol. Oncol. 112(2), 319-324 (2009).
113. Shigemasa K, Tanimoto H, Sakata K et al. Induction of matrix metalloprotease 7 is common in mucinous ovarian tumors including early stage disease. Med. Oncol. 17(1), 52-58 (2000). (Pubitemid 30159168)
114. Lu L, Katsaros D, Wiley A et al. Promoter-specific transcription of insulin-like growth factor II in epithelial ovarian cancer. Gynecol. Oncol. 103(3), 990-995 (2006). (Pubitemid 44821326)
115. Lu L, Katsaros D, Wiley A et al. The relationship of insulin-like growth factor II, insulin-like growth factor binding protein 3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin. Cancer Res. 12(4), 1208-1214 (2006). (Pubitemid 43342510)
116. Mabuchi S, Kawase C, Altomare DA et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol. Cancer Ther. 9(8), 2411-2422 (2010).
117. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol. Int. 59(5), 300-305 (2009).
118. Kobel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5(12), e232 (2008).
119. Su F, Lang J, Kumar A et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark. Insights 2, 369-375 (2007).
120. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol. 198(4), 351-356 (2008). (Pubitemid 351451941)
121. Lu D, Kuhn E, Bristow RE et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol. Oncol. 122(3), 560-566 (2011).
122. Greene MH, Feng Z, Gail MH. The importance of test positive predictive value in ovarian cancer screening. Clin. Cancer Res. 14(22), 7574; author reply 7577-7579 (2008).
123. Mcintosh M, Anderson G, Drescher C et al. Ovarian cancer early detection claims are biased. Clin. Cancer Res. 14(22), 7574; author reply 7577-7579 (2008).
124. Havrilesky LJ, Whitehead CM, Rubatt JM et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol. Oncol. 110(3), 374-382 (2008).
125. Palmer C, Duan X, Hawley S et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE 3(7), e2633 (2008).
126. Anderson GL, Mcintosh M, Wu L et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J. Natl Cancer Inst. 102(1), 26-38 (2010).
127. Andersen MR, Goff BA, Lowe KA et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol. Oncol. 116(3), 378-383 (2010).
128. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control. Clin. Trials 21(Suppl. 6), 251S-272S (2000).
129. Folkins AK, Jarboe EA, Roh MH, Crum CP. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol. Oncol. 113(3), 391-396 (2009).
130. Pinho S, Marcos NT, Ferreira B et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 249(2), 157-170 (2007). (Pubitemid 46452924)
131. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J. Clin. Oncol. 21(Suppl. 10), 200s-205s (2003).
132. Moore RG, Maclaughlan S. Current clinical use of biomarkers for epithelial ovarian cancer. Curr. Opin. Oncol. 22(5), 492-497 (2010).
133. Pitteri SJ, Jebailey L, Faca VM et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS ONE 4(11), E7916 (2009).
134. Gadducci A, Ferdeghini M, Castellani C et al. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55 and 75 kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. Gynecol. Oncol. 58(2), 184-188 (1995).
135. Naldini A, Morena E, Belotti D, Carraro F, Allavena P, Giavazzi R. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thromb. Haemost. 106(4), 705-711 (2011).
136. Morin PJ. Claudin proteins in ovarian cancer. Dis. Markers 23(5-6), 453-457 (2007). (Pubitemid 350176412)
137. Pyle-Chenault RA, Stolk JA, Molesh DA et al. VSGP/F-spondin: a new ovarian cancer marker. Tumour Biol. 26(5), 245-257 (2005). (Pubitemid 41243225)
138. Simon I, Liu Y, Krall KL et al. Evaluation of the novel serum markers B7 H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol. Oncol. 106(1), 112-118 (2007).
139. Dupont J, Tanwar MK, Thaler HT et al. Early detection and prognosis of ovarian cancer using serum YKL 40. J. Clin. Oncol. 22(16), 3330-3339 (2004). (Pubitemid 41103690)
140. Hogdall E, Fung ET, Christensen IJ et al. Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. Proteomics Clin. Appl. 4(12), 940-952 (2010).
141. Cho H, Kim JH. Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J. Histochem. Cytochem. 57(5), 513-521 (2009).
142. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol. Oncol. 96(2), 516-519 (2005). (Pubitemid 40127158)
143. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer 42(6), 768-778 (2006).
144. Gorelik E, Landsittel DP, Marrangoni AM et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14(4), 981-987 (2005). (Pubitemid 40478567)